课题基金 / 基金详情

Engineering a Functional Liver Graft for Treatment of End Stage Liver Disease

Engineering a Functional Liver Graft for Treatment of End Stage Liver Disease
设计功能性肝移植来治疗终末期肝病
批准号:
8463800
负责人:
Denver Michael Faulk
金额:
$1.61万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-01 至 2013-08-31

项目摘要

项目成果

Denver Michael Faulk的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):仅在美国,终末期肝病患者每年约有27,000例死亡。随着人口老龄化,这一数字预计只会增加。目前确定的治疗方法是原位移植。然而,由于需求量大,供体肝脏严重短缺。那些有幸接受移植的患者要承担慢性排斥反应的风险,以及终身免疫抑制治疗相关的发病率。这种治疗对老年患者尤其困难。本应用程序为终末期肝衰竭患者的植入式肝移植工程提供了一种再生医学策略。它基于三个基本概念:1)肝脏的天然ECM,包括三维基础结构和组成,是肝脏再生的理想和必需的基质;2)全肝ECM支架保留了三维宏观结构、天然微血管网络和胆汁引流系统;3)将移植的全肝ECM移植物置于适当的三维微环境中,可促进肝脏再生;具体来说,在肝功能衰竭患者中。本研究的目的是:(1)建立一种有效的三维肝支架移植方法,重点是系统地将实质细胞和非实质细胞移植到原位;(2)评估移植三维肝支架后宿主的反应。此外,本研究中开发的方法和技术向建立脱细胞化和再细胞化标准迈出了重要的一步,这对于成功生产用于器官移植和药物发现的第一个全功能生物工程肝脏是必要的。
英文摘要
DESCRIPTION (provided by applicant): Approximately 27,000 deaths occur annually in the United States alone from patients with end-stage liver disease. With an aging population, this number is only expected to increase. The current definitive treatment is orthotropic transplantation. However, due to high demand there exists a critical shortage of donor livers. Those patients fortunate enough to receive a transplant are burdened with the risk of chronic rejection and the morbidity associated with a lifelong regimen of immunosuppressant therapy. This treatment is especially difficult for elderly patients. This application addresses a regenerative medicine strategy for engineering an implantable liver graft for patients with end-stage liver failure. It is based upon three fundamental concepts: 1) the native ECM of the liver, including the three dimensional untrastructure and composition, represents an ideal and required substrate for liver regeneration, 2) whole liver ECM scaffolds retain the three-dimensional macrostructure, the native microvascular network, and the bile drainage system; allowing for complete recellularization of all native cell types, and 3) liver regeneration can be promoted when reseeded whole liver ECM grafts are placed in the appropriate three dimensional microenvironment; specifically, in-situ in patients with liver failure. The objectives f the proposed research are to (1) establish an effective method for reseeding a three- dimensional liver scaffold, with a focus on systematically seeding both parenchymal and non parenchymal cells in their native location and to (2) evaluate the host response to the implantation of a reseeded three- dimensional liver scaffold. Additionally, the methods and techniques developed in this study present an important step towards the establishment of decellularization and recellularization criteria necessary to successful produce the first fully functional bioengineered livers for organ transplantation and drug discovery.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.actbio.2013.09.006
发表时间: 2014-01
期刊: ACTA BIOMATERIALIA
影响因子: 9.7
作者: [Faulk, D. M., Carruthers, C. A., Warner, H. J., Kramer, C. R., Reing, J. E., Zhang, L., D'Amore, A., Badylak, S. F.]
通讯作者: Badylak, S. F.
A Novel Synthetic Vascular Graft Capable of Minimally-Invasive Controlled Expansion to Match Somatic Growth in Neonatal and Pediatric Patients
  • 批准号:
    9344808
  • 项目类别:
  • 资助金额:
    $14.94万
  • 财政年份:
    2017
  • 负责人:
    Denver Michael Faulk
  • 依托单位:
Engineering a Functional Liver Graft for Treatment of End Stage Liver Disease
海外基金